Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis – report of two filgotinib-treated cases and literature review
This report suggests that filgotinib may be considered for treating irEC refractory to standard therapy.
Authors
- Gudbjörg Sigurjonsdottir
- Björn Båtshake
- Henrik Ekedahl (ORCID: https://orcid.org/0000-0003-4337-8495)
- Viktoria Bergqvist
- Jan Marsal (ORCID: https://orcid.org/0000-0003-4808-0014)
- Ana Paula Carneiro (ORCID: https://orcid.org/0000-0003-3698-5748)
Institutions
- Lund University (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-10-07
- DOI
- https://doi.org/10.2340/1651-226x.2025.44298
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Biogen